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ABSTRACT: Irreversible covalent inhibitors can have a beneficial
pharmacokinetic/pharmacodynamics profile but are still often avoided
due to the risk of indiscriminate covalent reactivity and the resulting
adverse effects. To overcome this potential liability, we introduced an
alkyne moiety as a latent electrophile into small molecule inhibitors of
cathepsin K (CatK). Alkyne-based inhibitors do not show
indiscriminate thiol reactivity but potently inhibit CatK protease
activity by formation of an irreversible covalent bond with the
catalytic cysteine residue, confirmed by crystal structure analysis. The
rate of covalent bond formation (kinact) does not correlate with
electrophilicity of the alkyne moiety, indicative of a proximity-driven
reactivity. Inhibition of CatK-mediated bone resorption is validated in human osteoclasts. Together, this work illustrates the
potential of alkynes as latent electrophiles in small molecule inhibitors, enabling the development of irreversible covalent
inhibitors with an improved safety profile.
■ INTRODUCTION
Irreversible covalent inhibition of a target protein minimizes
the required systemic drug exposure as protein activity can
only be restored by de novo protein synthesis, resulting in a
prolonged therapeutic effect long after the compound is
cleared from the blood.1,2 Strategically placing an electrophilic
moiety on the inhibitor will allow it to undergo attack by a
nucleophilic amino acid residue upon binding to the target
protein, forming an (ir)reversible bond that is much stronger
than typical noncovalent interactions. However, the ability to
form a covalent bond with the target enzyme has raised
concerns about indiscriminate reactivity with off-target
proteins,3−5 even though some of the most prescribed drugs
are covalent irreversible binders.6,7 This led to the disfavor of
covalent modifiers as drug candidates until the recent
successful development of irreversible covalent kinase inhib-
itors ibrutinib and afatinib, which form an irreversible covalent
bond between an acrylamide warhead and a nonconserved
cysteine residue on the ATP-binding site2,8−10 but also with
nontargeted cellular thiols.11 The ability to form covalent
adducts with off-target proteins has been linked to an increased
risk of unpredictable idiosyncratic toxicity along with the daily
drug dose administered to patients.11−14 This risk can be
reduced by incorporating less reactive electrophilic moieties
into irreversible covalent inhibitors.
Terminal alkynes are generally considered “inert” toward
cellular components in the absence of radical initiators and are
therefore often used in bioorthogonal approaches as chemo-
selective “Click” handles.15,16 However, our group has shown a
C-terminal propargyl moiety on ubiquitin to react in an
activity-based manner with the catalytic cysteine residue in
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deubiquitinating enzymes (DUBs), forming an irreversible
thioether bond via an in situ thiol−alkyne addition (Scheme
1).17 Markovnikov hydrothiolation of (terminal) alkynes with
aliphatic thiols has been described for metal-catalyzed
reactions18−21 but has not been reported to occur outside
the active-site of a cysteine protease under physiological
conditions. The alkyne moiety on ubiquitin did not react with
cysteine residues present in nontargeted proteins nor with
excess thiol. Work by Sommer et al. revealed that the catalytic
triad does not have to be intact for covalent bond formation,
indicating a proximity-driven reactivity.22 Although it was
believed that the reactivity of the alkyne resulted from a
template effect: recognition of (large) protein fragments
driving the formation of the thermodynamically unfavored
Markovnikov-type thiovinyl product,23 here we show that
strong enough binding can be achieved with a small molecule
recognition part. This study highlights the potential of alkynes
as latent electrophiles in irreversible covalent small molecule
inhibitors, as demonstrated for cathepsin K (CatK).
CatK is a cysteine protease that is highly expressed in
osteoclasts and is the most important protease in bone
degradation.24 Implicated in diseases such as osteoporosis, its
inhibition has been of therapeutic interest for the past
decade.25 The most promising small molecule CatK inhibitor
to date was odanacatib (ODN),26 a nonlysosomotropic
inhibitor with a nitrile moiety as reversible covalent warhead
that binds to catalytic Cys25 (Figure S1). ODN has a high
selectivity for CatK versus other cathepsins and only has to be
taken once weekly because of its very long half-life of
66−93 h.27 The development was terminated after phase III
clinical trials showed side effects including increased stroke
risks and cardiovascular events.28−30 It is currently unclear
whether this is due to inhibition of nonskeletal degradation
properties of CatK or because of off-target inhibition.31
Nonetheless, the close proximity of the nitrile moiety relative
to Cys25 made it a suitable model to incorporate an alkyne
moiety as electrophile.
■ RESULTS AND DISCUSSION
Derivatives of ODN were obtained by functionalization of
precursor 1, as reported previously (Scheme 2 and Scheme
S1).32,33 Replacing the nitrile with an alkyne led to
compromised solubility in aqueous media for alkyne 3,
which could be overcome by removal of the hydrophobic
cyclopropane in nitrile 2, propargyl 4, and monomethylated
propargyl 5. The cyclopropane moiety is not essential for CatK
inhibition but was introduced in the development of ODN to
reduce metabolic liabilities.26 Alkyne electrophilicity increases
if an electron-withdrawing substituent is introduced on the
terminal position,19,34 while remaining less electrophilic than
acrylamides, and therefore, electron-deficient alkyne 6 was
taken along to investigate the effect of electrophilicity on the
inhibitor selectivity. Conjugate addition of cysteine to electron-
deficient internal alkynes in aqueous medium has been
reported and has recently been utilized in the irreversible
covalent kinase inhibitor acalabrutinib.19,35,36
Indiscriminate Thiol Reactivity. Indiscriminate thiol
reactivity was assessed following an established protocol in
which nitrile-based inhibitors form an irreversible covalent
adduct with cysteine37 (Table 1, Figure S2). Briefly,
compounds were incubated with cysteine for 23 h after
which they were analyzed by LC−MS. The adduct formation
was quantified from the UV trace. ODN and nitrile 2 show
adduct formation that increases upon increasing the pH of the
buffer, as do acrylamide-based inhibitors ibrutinib and afatinib
and irreversible pan-cathepsin inhibitor E-64.38 Adduct
formation was not detected for alkyne-based inhibitors 3−5,
which supports our hypothesis that the unactivated alkyne is
not reactive toward cysteine residues in nontargeted proteins.
As expected,36 adduct formation with electron-deficient
alkynes 6 and acalabrutinib was observed, underlining the
importance of alkyne electrophilicity in indiscriminate thiol
reactivity.
Glutathione (GSH), a tripeptide with a cellular concen-
tration of 0.5−10 mM,39 is a commonly used biological thiol to
assess the risk of iodiosyncratic toxicity. GSH adduct was
observed for acrylamides and electron-deficient alkynes, as
reported,11,36 but not for inhibitor 4 upon incubation with 5
mM GSH.
In Vitro Inhibition. A recurring issue in CatK drug
development is the difference in amino acids at the active-site
for rodentCatK compared to humanCatK, thus reducing the
apparent potency of ODN up to 182-fold in mice and rats.40
We therefore assessed the potency of our inhibitors in an in
vitro inhibition assay on recombinant human cathepsins
(Table 2). As reported, ODN is selective for hCatK with an
IC50 below 1 nM. Noncovalent interactions have been
optimized for ODN, and we anticipated that replacing the
polarized nitrile moiety by a nonpolarized alkyne moiety would
decrease the interaction with active-site residues, reducing the
noncovalent complex formation (kon), This is indeed reflected
in increased IC50 values for all alkyne-based inhibitors.
Scheme 1. Terminal Alkyne Moiety as Latent Electrophile
for Thiol−Alkyne Addition in (A) Ubiquitin-Based Activity
Probes Targeting DUB Proteases and (B) Irreversible
Covalent Small Molecule Inhibitors of Cysteine Protease
CatK
Scheme 2. Synthesis of ODN, Nitrile 2, Alkynes 3−5, and
Electron-Deficient Alkyne 6
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Selectivity for CatK over related human cathepsins was
conserved for alkynes 4 and 5, while all selectivity is lost for
electron-deficient alkyne 6. Inhibition of hCatK activity was
validated in a gel-based probe labeling experiment with
quenched activity-based probe BMV109 (Figure S3).
Binding Mode of Alkynes Is Irreversible and
Covalent. Reversibility of hCatK inhibition was assessed in
a jump dilution assay.41 Recombinant hCatK was incubated
with inhibitors at high concentration to allow full active-site
occupation and subsequently diluted 300-fold into fluorogenic
substrate (Z-FR-AMC) solution resulting in an increase of
substrate hydrolysis in case of reversible inhibition (Figure 1).
The progress curve shows that ODN is a (fast) reversible
inhibitor, while inhibition by alkynes 4−6 is irreversible.
The nature of the inhibitor−cathepsin interaction was
elucidated by LC−MS analysis of intact CatK and intact
CatK−inhibitor complexes (Figure 2). Recombinant hCatK
was incubated with inhibitor for 6 h to allow full covalent bond
formation and submitted for measurement. An increase in the
deconvoluted mass corresponding to addition of the inhibitor
to hCatK was observed for alkynes 4−6, confirming the
formation of a covalent hCatK−inhibitor complex.
The apparent potency of irreversible covalent inhibitors
increases upon longer incubation with the enzyme, since the
interaction of inhibitor with enzyme is not at equili-
brium.1,42−45 As a result, the potency of these compounds
can better be assessed by comparison of the kinact/KI ratio,
which can be derived from the progress curve of substrate
hydrolysis when the reaction is initiated by addition of the
enzyme (Table 3; more details in the SI).42 Interestingly, the
maximum rate of covalent bond formation (kinact) did not
correlate with reactivity of the alkyne, as kinact for alkynes 4 and
5 is faster than for electron-deficient alkyne 6. We hypothesize
that halogen bonding by the terminal bromine with the thiol
moiety on hCatK positions the alkyne less optimal relative to
the cysteine residue thus reducing the rate of proximity-driven
C−S bond formation.46 The rate of covalent bond formation
for ODN (k5) is faster than for the alkynes, also when
correcting for the reverse reaction (k6).
Alkynes Form a Covalent Thiovinyl Bond with
Catalytic Cysteine Residue. Covalent CatK−alkyne 4
complex was submitted to bottom-up proteomic analysis to
identify which amino acid residue is modified. In the tryptic
digestion of unreacted CatK, the various length variant
peptides containing the NQGQCGSCW-stretch have both
Cys22 and Cys25 labeled with a carbamidomethyl group due
to the alkylation reaction with iodoacetamide during the
sample processing (Figure S4A,B). After reaction with alkyne
4, these peptides disappear, but various peptides containing the
NQGQCGSCW-stretch appear labeled with one carbamido-
methyl group and one inhibitor. Tandem mass spectrometric
analysis by HCD and EThcD analysis of peptide NQGQCGS-
CWAFSSVGALEGQLKKK indicates inhibitor 4 is on the
second cysteine residue (Cys25, Figure S4C). Together, this
clearly shows that one of these cysteine residues is labeled,
most likely catalytic Cys25.
The formation of a vinyl thioether linkage between catalytic
Cys25 on hCatK and the internal carbon of the alkyne moiety
was confirmed by solving the crystal structure of CatK−
inhibitor 7 complex (Figure 3). Mature CatK was inactivated
Table 1. Indiscriminate Thiol Reactivitya
aAdduct formation quantified from LC−MS UV trace after 23 h
incubation with 10 mM cysteine or 5 mM GSH at 37 °C in buffer at
different pH values. bReversible adduct formation.
Table 2. In Vitro IC50 Values (M) against Proteolytic Activity of Cysteine Proteases
a
aIncubation of cysteine protease and inhibitor for 30 min prior to addition of fluorogenic substrate. Protease concentrations: hCatK (150 pM),
hCatL (5 pM), hCatS (1 nM), hCatV (25 pM), hCatB (1 nM), and papain (3 nM). Mean ± SD for a single representative experiment (triplicate
measurement). NA = not available. More details are available in the SI.
Figure 1. Jump dilution assay (A) 300-fold dilution of inhibitor
concentration from full inhibition to full activity. (B) Progress curves
for hCatK proteolytic activity after dilution in Z-FR-AMC. Control:
E-64 is an irreversible pan-cathepsin inhibitor.
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with MMTS for purification and storage and reactivated with
DTT in the presence of alkyne inhibitors at high concentration
(200 μM) to prevent self-degradation of CatK. Solubility of
alkynes 4 and 5 was not sufficient, which can be contributed to
the fluoroleucine moiety. We therefore synthesized alkyne 7, a
closely related derivative in which the fluorine on the L-leucine
building block was replaced by a proton to improve solubility
(Scheme S2). The resulting CatK−inhibitor 7 complex was
crystallized using a sitting drop method, and the structure
could be solved at 1.7 Å resolution using maximum-likelihood
free-kick (ML FK) electron density map47 (Figure S5). The
refined structure unambiguously revealed the presence of a
bond between the thiol atom of Cys25 and the internal carbon
in alkyne 7, with a C−S distance of 1.8 Å.
Inhibition of Bone Resorption Activity in Osteoclasts.
Having established the covalent, irreversible inhibition of CatK
on purified recombinant enzyme, we decided to test the
inhibitory properties in a biologically relevant setting;
inhibition of bone resorption by osteoclasts (OCs). OCs are
the cells that degrade the bone matrix by secretion of acid and
CatK into the resorption lacunae, resulting in the cleavage of
collagen type I. OCs are essential in bone repair, and aberrant
activity is observed in numerous diseases including osteopo-
rosis, rheumatoid arthritis, giant cell tumor of the bone, and
bone metastases.48−50
Inhibition of osteoclastic CatK was studied by culturing OCs
on cortical bone slices in the presence of inhibitor. Mature
OCs were obtained by treatment of CD14+ monocytes with
M-CSF (macrophage colony stimulating factor) and RANKL
(receptor activator of nuclear factor κB ligand) to stimulate
differentiation to mature OCs (Figure 4).51 Mature OCs are
formed by merging of mononuclear osteoclast precursors to
form large multinucleated cells, a process that continued until
the end of the culturing period. When the culturing medium
Figure 2. Representative ionization envelope (left) and deconvoluted
electrospray ionization mass spectrum (right) of (A) intact hCatK or
intact covalent complex with (B) inhibitor 4, (C) inhibitor 5, or (D)
inhibitor 6 upon incubation with excess inhibitor.
Table 3. In Vitro Kinetic Evaluation of CatK Inhibitiona
a100 pM recombinant hCatK, 4 μM fluorogenic substrate Z-FR-
AMC, 26 °C. Reaction initialization by addition of CatK. Mean ± SD
for a single representative experiment (triplicate measurement).
Information on data fitting to obtain kinetic constants is provided in
the SI.
Figure 3. Crystal structure of alkyne 7 bound covalent to catalytic
Cys25 in CatK. (A) Structure of inhibitor 7 before and after covalent
bond formation with CatK. (B) X-ray structure of inhibitor 7 bound
to Cys25 in CatK. PDB: 6QBS.
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was refreshed (every 3 days), inhibitor was freshly added to
make sure there always is inhibitor present to inhibit CatK in
the newly formed mature OCs. The OCs were cultured on
bone slices for sufficient time to clearly observe bone
resorption. After culturing for 21 days, the OCs were washed
off the bone slices and the resorption pits were stained to
visualize bone resorption activity. OCs with normal CatK
activity form trenches, resorbing the bone while they move
over the surface of the bone. Previously published observations
in OCs from CatK−/− mice show that OCs lacking CatK are
still able to form shallow pits, but unable to form trenches, with
accumulation of collagen I fragments in the lysosomes.52
Staining of bone slices for bone resorption showed
formation of deep trenches for samples treated with 3 nM
ODN, while 15 nM ODN resulted in the formation of shallow
pits (Figure 4C), corresponding to an effective dose of around
15 nM.53 Treatment with 4 successfully inhibited bone
resorption at concentrations from 80 nM, while inhibition
with 5 was nonconclusive; we observed trenches as well as pits
at all tested concentrations. Quantification of the total
resorption area confirmed these observations, even though it
is not possible to distinguish between shallow pits and deep
trenches (Figure S6). From this experiment, we concluded that
alkynes 4 and 5 are inhibitors of bone resorption with a higher
potency than expected based on their potency to inhibit
recombinant CatK.
Next, we treated the OC lysates with activity-based
cathepsin probe BMV109 to assess whether the observed
inhibition of bone resorption could be correlated with CatK
activity (Figure 4D,E). CatK activity for OCs treated with
DMSO is low, which is expected because mature CatK in its
uninhibited form is self-degrading,54 and the observed bone
resorption is the result of secreted mature CatK activity.
Additionally, we expect that intracellular CatK is predom-
inantly catalytic inactive pro-CatK, which is activated by
cleavage of the activation peptide, an autoproteolytic event that
requires an environment with a low pH for example lysosomes
and the resorption lacunae.55 Interestingly, we observe a strong
increase of mature CatK activity in all samples treated with
ODN, while samples with inhibitor 4 or 5 do not show any
CatK activity. The observed increase in mature CatK activity
for ODN-treated samples does not reflect the actual intra-
cellular proteolytic activity, but is the result of displacement of
reversibly bound ODN by excess of irreversible probe
BMV109. Alkynes 4 and 5 form an irreversible covalent
bond with CatK, and can thus not be displaced by BMV109.
Western blotting for CatK revealed an increase in the
intracellular levels of mature CatK for OCs that were treated
with high concentration of any inhibitor, which could be the
result of inhibition of proteolytic CatK activity, which would
normally degrade mature CatK.
Counting OCs that were cultured on plastic revealed an
increase in the number of OCs for the highest concentrations
of ODN, 4 and 5 (Figure S7). This is in agreement with
previous reports that observed an increase of OC maturation as
a response to CatK activity loss; the same number of bone
marrow cells from CatK−/− mice led to a greater number of
active OCs compared to bone marrow cells from the control
mice.52 A significant increase in CatK expression upon 100 nM
ODN treatment has been reported, without an increase in the
number of OCs.56 We hypothesize that complete inhibition of
CatK activity stimulates the maturation of OCs, and further
investigations to identify the feedback mechanism are ongoing.
■ CONCLUSION
To conclude, alkynes are not only suitable as latent
electrophiles in (large) peptides but also in small molecule
inhibitors, as shown here for inhibition of cysteine protease
cathepsin K (CatK). Alkyne-based covalent inhibitors do not
show indiscriminate thiol reactivity but do form an irreversible
Figure 4. Inhibition of CatK activity in human osteoclasts (OCs). (A) Maturation of OCs from monocytes. (B) CD14+ monocytes on bone slices
were treated with M-CSF (day 0) and RANKL (day 3) to stimulate differentiation to mature OCs. Medium containing either inhibitor or DMSO
was refreshed on day 7, 10, 13, and 16. At day 21, OCs were washed away and lysed, and bone slices were stained to visualize bone resorption. (C)
Bone resorption visualized by staining of resorption pits with Coomassie Brilliant Blue. More staining means more resorption pits and, thus, more
bone resorption activity. Normal OCs predominantly form deep trenches (paths), while OCs lacking CatK form small pits (circular dots). (D)
Schematic overview of CatK activation. (E) CatK activity and expression in OC lysates. Top: fluorescence scan of CatK bound to irreversible
activity-based probe BMV109 shows mature, active CatK. Middle/bottom: Western blotting against CatK shows total amount of CatK present in
OC lysates. Darker bands indicate more CatK activity/expression.
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covalent bond formation with CatK, as confirmed by MS
analysis of the (intact) CatK−inhibitor complexes. X-ray
crystallography confirmed the formation of the Markovnikov-
type product between the active-site cysteine thiol and the
internal carbon of the alkyne moiety. Kinetic evaluation shows
that the rate of covalent bond formation (kinact) does not
correlate with electrophilicity of the alkyne, supporting our
hypothesis of proximity-driven reactivity. Optimization of the
alkyne position relative to the cysteine residue could result in
more potent compounds with faster covalent bond formation
while not compromising on indiscriminate thiol reactivity.
Treatment of human osteoclasts (OCs) with alkynes 4 and 5
showed a potent inhibition of CatK-mediated bone resorption
activity, with only a 5-fold difference in effective dose between
ODN and inhibitor 4. Further investigations into the biological
effect of irreversible inhibition of CatK are ongoing.
Finally, we urge everyone using the alkyne moiety as a Click
handle to be careful with the assumption that the alkyne is
truly bioorthogonal; the binding of a small molecule inhibitor
can be strong enough to initiate a thiol−alkyne reaction when
the alkyne moiety is positioned in close proximity to a cysteine
residue. More importantly, based on the proof-of-concept
studies described herein, we foresee latent electrophiles such as
the alkyne to be of great value in future development of
cysteine-targeting covalent inhibitory drugs with a reduced risk
of idiosyncratic toxicity.
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